de Jong 1996.

Methods	Setting: The Netherlands, hospital outpatient clinic Randomisation: yes, method not stated Allocation concealment: unclear Design: parallel Intervention period: 2 weeks Masking: double blind Excluded: not stated Withdrawals: stated Baseline characteristics: comparable Jadad score=3
Participants	30 adults: 17M 13F Age range: 21‐46 years Inclusion criteria: Mild asthma and a history of episodic wheezing, dyspnoea Symptoms well controlled by inhaled bronchodilator FEV (% predicted) 55 or greater Methacholine BHR (PC20 FEV1) < 4mg/ml Exclusion criteria: Respiratory tract infection or asthma exacerbation in last 6 weeks
Interventions	BUD: 400mcg 1 pf 3xdaily (1200mcg/d) Placebo: 1 pf 3xdaily Delivery device: Turbuhaler DPI
Outcomes	FEV1 Methacholine BHR (PC20 FEV1) Requiring one or more courses or oral steroids for asthma exacerbation (number of patients)
Notes	No reply from author to clarify details of randomisation or provide numerical data for methacholine challenge. A principal aim of this study was to assess the effects of inhaled terbutaline on rebound airway obstruction and bronchial responsiveness during treatment with either budesonide or placebo. The data used here concerns the 2 week period prior to treatment with terbutaline when patients received only budesonide or placebo.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear